The stock of Endocyte, Inc. (NASDAQ:ECYT) is a huge mover today! About 122,674 shares traded hands. Endocyte, Inc. (NASDAQ:ECYT) has declined 6.23% since March 8, 2016 and is downtrending. It has underperformed by 15.55% the S&P500.
The move comes after 9 months negative chart setup for the $136.33M company. It was reported on Oct, 11 by Barchart.com. We have $2.75 PT which if reached, will make NASDAQ:ECYT worth $13.63 million less.
Analysts await Endocyte, Inc. (NASDAQ:ECYT) to report earnings on November, 1. They expect $-0.29 EPS, down 20.83% or $0.05 from last year’s $-0.24 per share. After $-0.25 actual EPS reported by Endocyte, Inc. for the previous quarter, Wall Street now forecasts 16.00% negative EPS growth.
Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage
Out of 2 analysts covering Endocyte (NASDAQ:ECYT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Endocyte has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 4. Credit Suisse initiated the shares of ECYT in a report on Thursday, January 21 with “Outperform” rating. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, August 5.
According to Zacks Investment Research, “Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based in West Lafayette, Indiana.”
Insitutional Activity: The institutional sentiment decreased to 0.87 in Q2 2016. Its down 0.25, from 1.12 in 2016Q1. The ratio is negative, as 10 funds sold all Endocyte, Inc. shares owned while 29 reduced positions. 9 funds bought stakes while 25 increased positions. They now own 15.26 million shares or 5.31% less from 16.12 million shares in 2016Q1.
Brave Asset accumulated 0% or 500 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Blackrock Institutional Na holds 518,217 shares or 0% of its portfolio. Deutsche Retail Bank Ag has invested 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Jpmorgan Chase And has 0% invested in the company for 782,485 shares. Hall Laurie J Trustee holds 0% or 270 shares in its portfolio. The Texas-based Hilltop Hldgs Inc has invested 0.01% in Endocyte, Inc. (NASDAQ:ECYT). Concannon Wealth Mngmt Limited Co last reported 0.11% of its portfolio in the stock. Blackrock Japan Ltd has 4,939 shares for 0% of their US portfolio. First Financial Corporation In holds 0% or 100 shares in its portfolio. Camarda Financial Advsrs Limited Liability Company, a Florida-based fund reported 1,000 shares. Geode Mgmt Ltd Limited Liability Company holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 242,815 shares. The Illinois-based Rmb Mngmt Ltd Liability Corporation has invested 0.04% in Endocyte, Inc. (NASDAQ:ECYT). Manufacturers Life The holds 1,496 shares or 0% of its portfolio. Pinnacle Associates has invested 0.06% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT).
Insider Transactions: Since May 10, 2016, the stock had 1 buy, and 0 sales for $40,040 net activity. Low Philip S bought 11,375 shares worth $40,040.
More recent Endocyte, Inc. (NASDAQ:ECYT) news were published by: Quotes.Wsj.com which released: “Endocyte Inc. ECYT (US: Nasdaq)” on August 20, 2010. Also Fool.com published the news titled: “Why Endocyte Inc. Shares Plummeted in After Hours” on June 18, 2014. Ibj.com‘s news article titled: “CEO Ellis resigns after 20 years at struggling drug firm Endocyte” with publication date: June 21, 2016 was also an interesting one.
ECYT Company Profile
Endocyte Inc. (Endocyte), incorporated on December 11, 2001, is a biopharmaceutical company. The Firm is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), PSMA Tubulysin (EC1169), Vintafolide (Folate DAVLBH), Folate-DNA alkylator (EC1788), Folate-Aminopterin (EC1669), Folate-mTor inhibitor (EC0371), Etarfolatide (Folcepri or Tc99m) and PSMA- Tc99m (EC0652).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.